152 related articles for article (PubMed ID: 18091052)
1. Obesity is not predictive of overall survival following permanent prostate brachytherapy.
Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Adamovich E
Am J Clin Oncol; 2007 Dec; 30(6):588-96. PubMed ID: 18091052
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
3. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
Merrick GS; Galbreath RW; Butler WM; Waller KE; Allen ZA; Lief J; Adamovich E
Cancer; 2007 Jul; 110(2):289-96. PubMed ID: 17549691
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
[TBL] [Abstract][Full Text] [Related]
5. Prostate brachytherapy in men > or =75 years of age.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Adamovich E
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):415-20. PubMed ID: 18374514
[TBL] [Abstract][Full Text] [Related]
6. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
7. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
[TBL] [Abstract][Full Text] [Related]
8. Primary causes of death after permanent prostate brachytherapy.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
[TBL] [Abstract][Full Text] [Related]
9. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
10. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
[TBL] [Abstract][Full Text] [Related]
11. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
[TBL] [Abstract][Full Text] [Related]
13. The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Shetti MB; Merrick GS; Butler WM; Galbreath R; Torlone A; Lief JH; Adamovich E; Wallner KE
Am J Clin Oncol; 2012 Dec; 35(6):572-9. PubMed ID: 22134514
[TBL] [Abstract][Full Text] [Related]
14. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief J; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e225-32. PubMed ID: 21664066
[TBL] [Abstract][Full Text] [Related]
15. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Adamovich E; Wallner KE
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1104-10. PubMed ID: 20864268
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
[TBL] [Abstract][Full Text] [Related]
17. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Brammer SG; Allen ZA; Lief JH; Adamovich E
Am J Clin Oncol; 2008 Dec; 31(6):539-44. PubMed ID: 19060584
[TBL] [Abstract][Full Text] [Related]
19. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
[TBL] [Abstract][Full Text] [Related]
20. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]